The US Food and Drug Administration (US FDA) has concluded a routine inspection of Lannett Company LLC, a wholly owned step-down subsidiary of Aurobindo Pharma USA Inc., with four observations.

The inspection was conducted at Lannett Company's manufacturing facility in Seymour, Indiana, USA, from August 17 to 21, 2026.

According to a regulatory filing by Aurobindo Pharma, the inspection concluded with four observations, which the company described as procedural in nature. The company said it will respond to the US FDA within the stipulated timeline.

Aurobindo Pharma said it remains committed to maintaining robust quality and compliance standards across its manufacturing facilities.

The company added that it will keep the stock exchanges informed of any further developments related to the inspection, in accordance with applicable regulatory requirements.